Results 151 to 160 of about 681,456 (227)

Toward Regulatory Convergence and Streamlined Biosimilar Development: Recommendations from an International Qualitative Study. [PDF]

BioDrugs
Car E, Barbier L, Schwarzenberger I, Huys I, Simoens S, Vulto AG.   +5 more
europepmc   +1 more source

Drugs anticipated to be selected for Medicare price negotiation in 2026 for implementation in 2028. [PDF]

J Manag Care Spec Pharm
Cousin EM, Martin K, Hansen RN, Coster J, Sullivan SD.   +4 more
europepmc   +1 more source

Regulatory Definitions and Classification of Biosimilar Medications Across the 6 Regions of the World Health Organization: A Scoping Review.

JAMA Health Forum
Watanabe JH, Strand MW, Walvekar M, Alfonso-Cristancho R.   +3 more
europepmc   +1 more source

Biological Medicines, Biosimilars and Their Automatic Substitution: Concerns, Knowledge and Information Needs of People with Diabetes. [PDF]

BioDrugs
Kouhia M, Linden K, Metso S, Pimiä E, Koski S, Aarnio E, Zacheus T, Hämeen-Anttila K.   +7 more
europepmc   +1 more source

Evaluation of a New Potential Bevacizumab Biosimilar in Corneal Neovascularization. [PDF]

Turk J Ophthalmol
Özgür A, Yeşilırmak N, İnan MA, Bağrıaçık EÜ, Özmen MC.   +4 more
europepmc   +1 more source

Switching From Intravitreal Ranibizumab (Lucentis) to Biosimilar Ranibizumab (Ongavia) Injections: Insights From a Tertiary Care Eye Centre. [PDF]

Cureus
Sourla E, Zaheer N, Chavan R.
europepmc   +1 more source

Biosimilar Versus Innovator Ranibizumab in Myopic CNVM: Comparative Real-World Outcomes- The BRIM Study. [PDF]

Clin Ophthalmol
Chakraborty D, Sinha TK, Sinha S, Biswas RK, Maiti A, Nandi K, Rungta D, Bhattacharya R.   +7 more
europepmc   +1 more source

A Phase III Randomized Trial Comparing Efficacy, Safety, and Immunogenicity of ZRC-3285 vs. Eylea^® in Patients with Wet Age-Related Macular Degeneration. [PDF]

Ophthalmol Ther
Bansal M, Singh P, Mehta RK, Laul RS, Rana P, Shah U, Vohra R, Desai S, Bhomaj S, Patwardhan S, Manoher JM, Sapar A, Parwal S, Amabde AK, Shroff R, Natesh S, Biswas RK, D LR, Sinha BP, C K M, Patel E, Kamble A, Bhende P, Patil S, Shah A, Narula R, Kumari B, Bathula L, Kirtane S, Darji B, Doshi M, Parmar D.   +31 more
europepmc   +1 more source

Real-world efficacy and safety of transarterial chemoembolization plus sintilimab and bevacizumab biosimilar for intermediate-advanced hepatocellular carcinoma: a propensity score matching study. [PDF]

Front Immunol
Deng LW, Liu JF, Yu HY, Peng B, Liu B, Feng SF, Liu DX, Sun YY, Chen Y, Chen JJ, Zhang C, Wang HQ, Xu GH, Liu L, Wei G, Ren Y, Cao L, Zhao Y, Yang XG.   +18 more
europepmc   +1 more source

Implications of relying on manufacturer patient support programs for access to high-cost specialty and biologic medicines: a critical qualitative study. [PDF]

BMJ Open
Grundy Q, Hart D, Lexchin J, Persaud N, Tadrous M, Gagnon MA.   +5 more
europepmc   +1 more source